Recombinant Attenuated Salmonella Typhi Vaccine Vectors Producing Streptococcus Pneumoniae PspA
NCT01033409
Completed
In this Phase I clinical study, three recombinant, avirulent Salmonella Typhi (RASV) strains each expressing the Streptococcus pneumoniae surface protein, PspA, will be compared as live biological vaccine vectors to evaluate safe and tolerable, single, oral dose levels in adult subjects.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
11/01/2011
Locations: Saint Louis University Center for Vaccine Development, St. Louis, Missouri
Conditions: Pneumonia
Register for Updates
Study Evaluating Prevnar Infant Long-term Immune Response Versus Prevnar Naive Cohort
NCT00824850
Completed
The purpose of this study is to assess the "late" immune response to further doses of pneumococcal conjugate vaccine more than 10 years after primary immunization with Prevnar (7vPnC) in infancy, as compared with individuals who did not receive Prevnar in infancy (the Prevnar naive cohort which received MnCC). The study will take place at a single study center. Study participants must have participated previously in a specific Wyeth Prevnar study (Study D118-P8) and must still be enrolled in the... Read More
Gender:
ALL
Ages:
Between 8 years and 16 years
Trial Updated:
10/05/2011
Locations: Pfizer Investigational Site, Hayward, California +1 locations
Conditions: Pneumococcal Conjugate Vaccine
Register for Updates
Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma
NCT00002748
Completed
RATIONALE: Inserting the gene for interleukin-2 into a person's neuroblastoma cells may make the body build an immune response and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of using interleukin-2 gene-modified neuroblastoma cells in treating children who have refractory or recurrent neuroblastoma.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
10/03/2011
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Neuroblastoma
Register for Updates
A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly
NCT00952276
Completed
The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine in adults and the elderly. Primary Objectives: * To describe the immunogenicity of the candidate vaccines after a single injection. * To describe the safety of the candidate vaccines after a single injection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/26/2011
Locations: Not set, Anaheim, California +14 locations
Conditions: Influenza, Swine-origin A/H1N1 Influenza
Register for Updates
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
NCT00355121
Completed
The purpose of this study is to evaluate the immunogenicity and safety of the concomitant administration of Menactra® vaccine and DAPTACEL® vaccine. The main objectives are: Immunogenicity: To evaluate the antibody responses to both vaccines when Menactra vaccine is given concomitantly with DAPTACEL® compared to when either vaccine is given alone. Safety: To evaluate the rate of local and systemic reactions when DAPTACEL® and Menactra vaccines are administered concomitantly compared to when... Read More
Gender:
ALL
Ages:
Between 4 years and 7 years
Trial Updated:
08/22/2011
Locations: Not set, Little Rock, Arkansas +25 locations
Conditions: Meningococcal Meningitis, Tetanus, Diphtheria, Pertussis, Poliomyelitis
Register for Updates
Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS
NCT00574548
Completed
The objective of this study is to compare the safety, tolerability and immunologic response to a dose of 23vPS or 13vPnC given one year after either 13vPnC or 23vPS in subjects that have never received a previous dose of 23vPS.
Gender:
ALL
Ages:
Between 60 years and 64 years
Trial Updated:
07/18/2011
Locations: Pfizer Investigational Site, Chandler, Arizona +5 locations
Conditions: Pneumococcal Vaccines
Register for Updates
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
NCT00094653
Completed
The purpose of this study is to determine the safety and efficacy of MDX-010 (ipilimumab, BMS-734016) (anti-CTLA4) in combination with MDX-1379 (gp100, BMS-734019) in patients with previously treated, unresectable Stage III or IV melanoma. Survival time will be evaluated, as well as patient responses and time to disease progression. Eligible patients are those who in response to a single regimen containing interleukin-2 (IL-2), dacarbazine, and/or temozolomide, have 1) relapsed following an obje... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2011
Locations: Arizona Cancer Center, Tucson, Arizona +208 locations
Conditions: Melanoma, Metastases
Register for Updates
In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation
NCT00861107
Completed
This is a Phase I/II study to investigate the feasibility of creating a personalized therapeutic cancer vaccine within the body. A vaccine contains a source of tumor antigen and an adjuvant. In this study, tumor antigen is generated by freezing a tumor by a minimally invasive percutaneous (through the skin) cryoablation procedure. The study drug, AlloStim, is injected into the ablated tumor to promote development of an anti-tumor immune response.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2011
Locations: Immunovative Clinical Research, Inc, Carlsbad, California
Conditions: Metastatic Cancer
Register for Updates
Tumor Cell Vaccine in Treating Patients With Advanced Cancer
NCT00002505
Completed
RATIONALE: Vaccines made from the patient's cancer cells may make the body build an immune response and kill their tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of autologous tumor cell vaccination plus immunologic adjuvant in treating patients who have metastatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/10/2011
Locations: Hoag Memorial Hospital Presbyterian, Newport Beach, California +3 locations
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Immunogenicity to Human Papillomavirus Vaccine (Gardasil) Among IBD Patients on Immunosuppressive Therapy
NCT00727636
Completed
Many IBD patients take immunosuppressive agents and we are uncertain as to their capacity to mount a truly protective response after vaccination. If IBD patients do not have an adequate immunological response, they may need to increase the dosage or get booster shots. Many clinicians who treat patients with autoimmune diseases are asking if the vaccine is safe and effective. Thus, this study has important clinical and public health significance because more than one million people in the United... Read More
Gender:
FEMALE
Ages:
Between 9 years and 26 years
Trial Updated:
05/03/2011
Locations: Children's Hospital Boston, Boston, Massachusetts
Conditions: Inflammatory Bowel Disease
Register for Updates
Adolescents' Response to Hepatitis B Vaccine Booster Dose
NCT01341275
Unknown
The aims of this study are to determine: 1. the degree of immunity against hepatitis B, 2. factors associated with immunity against hepatitis B, 3. if the amount of antigen provided in a booster dose (used to measure the degree of immune memory) affects the body's response to the booster, and 4. if the age at which the vaccination was initiated during infancy affects duration of protection against hepatitis B among adolescents 16-19 years of age born in the United States who were immunized agai... Read More
Gender:
ALL
Ages:
Between 16 years and 19 years
Trial Updated:
04/22/2011
Locations: Texas Children's Hospital, Houston, Texas +1 locations
Conditions: Hepatitis B
Register for Updates
Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers
NCT00279734
Completed
Study to assess the ability of healthy subjects to build anitbodies to tetanus and pneumococcal vaccines after receiving a single intravenous dose of Abatacept, a drug which is being developed for the treatment of Rheumatoid Arthritis and which can affect the immune system.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/11/2011
Locations: Qutintiles Phase I Services, Lenexa, Kansas +2 locations
Conditions: Rheumatoid Arthritis
Register for Updates